LONDON, UK / ACCESSWIRE / January 16, 2018 / Active-Investors.com has just released a free earnings report on Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=APDN. The Company posted its financial results on December 28, 2017, for the fourth quarter of the fiscal year 2017. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Applied DNA Sciences most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=APDN

Earnings Highlights and Summary

For the three months ended September 30, 2017, Applied DNA's total revenues decreased 30% to $1.15 million from $1.64 million in Q4 FY16, due to a decreased sales to the textile industry. The Company's revenue numbers were below analysts' expectations of $1.90 million.

During FY17, the Company's total revenue increased 13% to $4.75 million from $4.19 million in FY16.

For the reported quarter, the Company's adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) was negative $1.70 million compared to negative $1.66 million in Q4 FY16.

During FY17, the Company's adjusted EBITDA was negative $8.29 million compared to negative $9.25 million in FY16.

During Q4 FY17, the Company's operating expenses increased 2.9% to $3.72 million from $3.61 million in the same period of last year.

For the reported quarter, the Company's operating loss was $2.84 million compared to an operating loss of $2.41 million in Q4 FY16.

During FY17, the Company's operating loss was $12.82 million compared to an operating loss of $12.20 million in FY16.

During Q4 FY17, Applied DNA's earnings before tax (EBT) was negative $2.85 million versus negative $2.42 million in the comparable period of last year.

For the reported quarter, Applied DNA's net loss was $2.85 million compared to a net loss of $2.42 million in Q4 FY16. During Q4 FY17, the Company's diluted earnings per share (EPS) was on par with the negative $0.10 reported in the corresponding period of last year, but was below analysts' expectations of negative $0.09.

During FY17, the Company's net loss was $12.86 million compared to a net loss of $12.18 million in FY16. During FY17, the Company's diluted EPS was negative $0.49 compared to negative $0.51 in FY16.

Balance Sheet

As on September 30, 2017, Applied DNA's cash and cash equivalents decreased 33.9% to $2.96 million from $4.48 million as on September 30, 2016.

For the reported quarter, the Company's net accounts receivable decreased 59.4% to $2.59 million from $6.37 million in Q4 FY16. For the reported quarter, Applied DNA's accounts payable and accrued liabilities decreased 58% to $0.94 million from $2.25 million in Q4 FY16.

During FY17, the Company's net cash provided by operating activities was negative $7.48 million compared to negative $9.90 million in FY16.

On December 18, 2017, Applied DNA and Colorcon entered into a technology license memorandum of understanding (MOU) that combines Applied DNA's proprietary molecular taggant and authentication technology with Colorcon's portfolio of film coating systems, inks, and color dispersions for use in solid oral dosage forms in the pharmaceutical and nutraceutical industries. The MOU is non-binding and is expected to be followed by a definitive agreement.

On December 20, 2017, the Company entered into a securities purchase agreement with certain institutional investors to purchase an aggregate of 2,735,000 shares of common stock, and warrants to purchase an aggregate of 2,735,000 shares of common stock in a registered direct offering. The offering closed on December 22, 2017, with net proceeds anticipated to be approximately $4.2 million, exclusive of warrant exercise proceeds.

Stock Performance Snapshot

January 12, 2018 - At Friday's closing bell, Applied DNA Sciences' stock fell 3.18%, ending the trading session at $1.52.

Volume traded for the day: 236.72 thousand shares, which was above the 3-month average volume of 190.68 thousand shares.

After last Friday's close, Applied DNA Sciences' market cap was at $41.63 million.

The stock is part of the Technology sector, categorized under the Security Software & Services industry. This sector was up 0.5% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visithttp://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors